Doctors at the Memorial Sloan Kettering Cancer Center (USA) achieved complete remission in 12 patients with rectal cancer using the immunotherapy drug dostarlimab. This is reported in an article published in The New England Journal of Medicine.
Dostarlimab is a monoclonal antibody that functions as a checkpoint inhibitor, prevents suppression of the immune system and helps it fight against cancer cells. This drug was administered every three weeks for six months to patients with stage II or III rectal adenocarcinoma. As planned by the researchers, the treatment should have been accompanied by standard chemoradiotherapy and surgery.
All 12 patients were in complete remission with no evidence of tumor on magnetic resonance imaging, positron emission tomography, endoscopy, digital rectal examination, or biopsy. None of the study participants received chemoradiotherapy or underwent surgery. There were also no reported cases of progression or recurrence during follow-up (range 6 to 25 months).
Earlier it was reported that scientists from the UK have developed a combination of drugs that is twice as effective as conventional chemotherapy against lung cancer.